IRVINE, Calif. --- Ivantis, a developer of novel intraocular devices designed to treat glaucoma by lowering the intraocular pressure (IOP) in the eye, announced today the 6-month results from its multi-center, international Hydrus I study at the European Society of Cataract and Refractive Surgery Meeting (ESCRS).  The results are being presented by Manfred Tetz, MD (Berlin, Germany), PI and first European surgeon to implant the Hydrus device.

Ivantis’ Hydrus™Intracanalicular Implant, roughly the size of an eyelash, is placed through a minimally invasive, microsurgical procedure and is designed to reduce eye pressure by reestablishing the patient’s conventional outflow pathway.  Most often, glaucoma patients have both a blockage and a collapse of the natural outflow pathway.  The Hydrus device relies on a twofold mechanism of action that creates a relatively large opening through the traditional source of flow blockage (known as the “trabecular meshwork)”, and then dilates and scaffolds the most critical quadrant of the outflow pathway through which fluid exits the eye (known as “Schlemm’s canal”).

The Hydrus I study was a prospective clinical trial at 6 centers that included 69 patients with mild-to-moderate glaucoma (the largest population of glaucoma) and was intended to assess the safety and efficacy of the Hydrus implant in two distinctly different surgical settings.  29...